- Conditions
- Immune Thrombocytopenia
- Interventions
- Second Line ITP agents
- Drug
- Lead sponsor
- Boston Children's Hospital
- Other
- Eligibility
- 1 Year to 18 Years
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2017
- U.S. locations
- 26
- States / cities
- Little Rock, Arkansas • Los Angeles, California • Oakland, California + 22 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–5
of 5
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Choroidal Neovascularization, Age-related Macular Degeneration
- Interventions
- hI-con1, ranibizumab, Sham injection
- Biological · Other
- Lead sponsor
- Iconic Therapeutics, Inc.
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 88 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 48
- States / cities
- Phoenix, Arizona • Arcadia, California • Beverly Hills, California + 44 more
- Conditions
- Uveal Melanoma, Choroid Neoplasm
- Interventions
- ICON-1
- Biological
- Lead sponsor
- Iconic Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 8
- States / cities
- San Francisco, California • Denver, Colorado • Leawood, Kansas + 5 more
- Conditions
- Choroidal Neovascularization, Wet Macular Degeneration
- Interventions
- ICON-1, aflibercept
- Biological
- Lead sponsor
- Iconic Therapeutics, Inc.
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 8
- States / cities
- Beverly Hills, California • Santa Ana, California • Syracuse, New York + 5 more
- Conditions
- MAC Lung Disease, Treatment Refractory MAC Lung Disease, Mycobacterium Infections, Nontuberculous
- Interventions
- Clofazimine Inhalation Suspension, Placebo
- Drug
- Lead sponsor
- Mannkind Corporation
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 132 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 54
- States / cities
- Birmingham, Alabama • Fresno, California • Los Angeles, California + 47 more